Clearmind Signs Development and Supply Agreement to Produce its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
This psychedelic makes you feel drunk. Could it be used to treat alcoholism?
5-Methoxy-2-aminoindane (MEAI) is a synthetic molecule that simulates the euphoric feeling of alcohol while reducing the desire to drink.
Pre-clinical studies conducted by Clearmind Medicine Inc. (CMND) show promising evidence that MEAI could treat alcohol use disorder (AUD) and binge drinking. Clinical trials expected to begin in the second half of 2022.
The company just signed a development and supply agreement with Aragen Life Sciences to manufacture the molecule.